针对线粒体的聚合脂质体用于预miRNA成像和基因治疗
Xiangdan Meng1, Junyan Yang2, Sirong Sun2
1Beijing Key Laboratory for Bioengineering and Sensing Technology, Research Centre for Bioengineering and Sensing Technology, School of Chemistry and Biological Engineering, University of Science and Technology, Beijing 100083, China.
Analytical chemistry
|July 29, 2025
概括
我们开发了适应pH的脂质体,以向线粒体输送核酸,使得前微RNA-34a成像和微RNA-34a基因疗法用于癌症治疗具有良好的生物相容性.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 分子生物学分子生物学
背景情况:
- 与线粒体相关的microRNAs (miRNAs) 对线粒体功能和疾病发病至关重要.
- 在将核酸输送到线粒体以用于成像和治疗应用方面存在挑战.
- 需要有针对性的交付系统来克服这些局限性.
研究的目的:
- 开发适应pH的脂质体,用于向线粒体输送核酸探针和治疗剂.
- 为了使癌细胞中的pre-microRNA-34a成像和miRNA-34a基因治疗成为可能.
- 研究这些脂质体在癌症诊断和治疗中的潜力.
主要方法:
- 响应pH的脂质体 (R@DA-TPP-SA) 自组装,封装DNA探针和小干扰RNA (siRNA).
- 线粒体向通过三啡 (TPP) 修饰来促进.
- 由酸性pH触发的DNA探针的细胞内释放,导致光成像的杂交连锁反应 (HCR).
- 溶酶体逃逸和siRNA的向传递到线粒体,用于基因沉默.
主要成果:
- 在A549癌细胞中成功对pre-microRNA-34a进行成像,显著增强光.
- 针对性地将siRNA传递到线粒体,导致抑制目标基因表达和破坏线粒体膜潜力.
- 诱导癌细胞亡,并证明了在体外和体内都具有抗癌功效.
- 脂质体表现出良好的生物相容性和低毒性.
结论:
- 开发出的pH响应性脂质体有效地向线粒体进行核酸输送.
- 该系统可同时进行miRNA成像和基因治疗,用于癌症治疗.
- 这些发现为诊断和治疗与线粒体功能障碍相关的疾病提供了一个有希望的平台.
更多相关视频
08:29Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
10.2K
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
10.8K
相关概念视频
01:22MicroRNAs
21.6K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.6K
00:59Gene Therapy
25.8K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.8K